A role for FGF2 in visceral adiposity-associated mammary epithelial transformation

References

• Ahn J, Schatzkin A, Lacey JV, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19):2091–2102. doi:10.1001/archinte.167.19.2091.
   PubMedGoogle Scholar
• Connolly BS, Barnett C, Vogt KN, et al. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer. 2002;44(2):127–38. doi: 10.1207/S15327914NC4402_02
   PubMed Web of Science ®Google Scholar
• Gaudet MM, Carter BD, Patel AV, et al. Waist circumference, body mass index, and postmenopausal breast cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Cancer Causes Control. 2014 June 01;25(6):737–745. doi:10.1007/s10552-014-0376-4
   PubMed Web of Science ®Google Scholar
• Hajian-Tilaki KO, Gholizadehpasha AR, Bozorgzadeh S, et al. Body mass index and waist circumference are predictor biomarkers of breast cancer risk in Iranian women. Med Oncol. 2011 Dec;28(4):1296–301. doi:10.1007/s12032-010-9629-6
   PubMed Web of Science ®Google Scholar
• Huang Z, Willett W, Coldfe G, et al. Waist circumference, waist:hip ratio, and risk of breast cancer in the nurses' health study. Am J Epidemiol. 1999 04/08/1999;150(2):8.
   Google Scholar
• Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003 Aug;4(3):157–73. doi:10.1046/j.1467-789X.2003.00108.x
   PubMedGoogle Scholar
• Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer – endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab. 2007 Apr;3(4):345–54. doi:10.1038/ncpendmet0456
   PubMedGoogle Scholar
• Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010 Jan;11(1):11–8. doi:10.1111/j.1467-789X.2009.00623.x
   PubMed Web of Science ®Google Scholar
• Kwon H, Kim D, Kim JS. Body fat distribution and the risk of incident metabolic syndrome: a longitudinal cohort study. Sci Rep. 2017 Sep 08;7(1):10955. doi:10.1038/s41598-017-09723-y
   PubMedGoogle Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014 Aug;105(2):141–50. doi:10.1016/j.diabres.2014.04.006
   PubMed Web of Science ®Google Scholar
• Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014 Apr 11;15(4):6184–223. doi:10.3390/ijms15046184
   PubMed Web of Science ®Google Scholar
• Kabat GC, Kim MY, Lee JS, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2017 Sep 22;26(12):1730–1735. doi:10.1158/1055-9965.EPI-17-0495
   PubMed Web of Science ®Google Scholar
• Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9(2):R23. doi:10.1186/bcr1665
   PubMed Web of Science ®Google Scholar
• Huffman DM, Augenlicht LH, Zhang X, et al. Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc(1638N/+) female mice. Cancer Prev Res (Phila). 2013 Mar;6(3):177–87. doi:10.1158/1940-6207.CAPR-12-0414
   PubMed Web of Science ®Google Scholar
• Lu YP, Lou YR, Bernard JJ, et al. Surgical removal of the parametrial fat pads stimulates apoptosis and inhibits UVB-induced carcinogenesis in mice fed a high-fat diet. Proc Natl Acad Sci U S A. 2012 Jun 05;109(23):9065–70. doi:10.1073/pnas.1205810109
   PubMed Web of Science ®Google Scholar
• Wittwer JA, Robbins D, Wang F, et al. Enhancing mitochondrial respiration suppresses tumor promoter TPA-Induced PKM2 expression and cell transformation in skin epidermal JB6 cells. Cancer Prevention Research. 2011;4(9):1476–1484. doi:10.1158/1940-6207.capr-11-0028.
   PubMed Web of Science ®Google Scholar
• Chang A, Yeung S, Thakkar A, et al. Prevention of skin carcinogenesis by the beta-blocker carvedilol. Cancer Prev Res (Phila). 2015 Jan;8(1):27–36. doi:10.1158/1940-6207.CAPR-14-0193
   PubMed Web of Science ®Google Scholar
• Lu FJ, Tseng TH, Lee WJ, et al. Promoting neoplastic transformation of humic acid in mouse epidermal JB6 Cl41 cells. Chem Biol Interact. 2006 Sep 25;162(3):249–58. doi:10.1016/j.cbi.2006.07.007
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Benham V, Bullard B, et al. Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer [Original Article]. Oncogene. 2017; 36(48):6668–6679. doi:10.1038/onc.2017.278.
   PubMed Web of Science ®Google Scholar
• Pang Y, Li W, Ma R, et al. Development of human cell models for assessing the carcinogenic potential of chemicals. Toxicol Appl Pharmacol. 2008 Nov 01;232(3):478–86. doi:10.1016/j.taap.2008.08.009
   PubMed Web of Science ®Google Scholar
• Balmain A, Harris C. Carcinogenesis in mouse and human cells- parallels and paradoxes. Carcinogenesis. 2000;12(3):371–377. doi:10.1093/carcin/21.3.371.
   Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006 Jun 09;281(23):15694–700. doi:10.1074/jbc.M601252200
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 June 21, 1996;271(25):15292–15297. doi:10.1074/jbc.271.25.15292.
   PubMed Web of Science ®Google Scholar
• Schapira D, Clar R, Wolff P, et al. Visceral obesity and breast cancer risk. Cancer. 1994;74(2):632. doi:10.1002/1097-0142(19940715)74:2%3c632::AID-CNCR2820740215%3e3.0.CO;2-T.
   PubMed Web of Science ®Google Scholar
• Rankinen T, Kim SY, Pérusse L, et al. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes. 1999;23(8):801–809. doi:10.1038/sj.ijo.0800929.
   PubMed Web of Science ®Google Scholar
• Brady N, Chuntova P, Bade LK, et al. The FGF/FGFR axis as a therapeutic target in breast cancer. Expert Rev Endocrinol Metab. 2013 Jul;8(4):391–402. doi:10.1586/17446651.2013.811910
   PubMedGoogle Scholar
• Welm BE, Freeman KW, Chen M, et al. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol. 2002 May 13;157(4):703–14. doi:10.1083/jcb.200107119
   PubMed Web of Science ®Google Scholar
• Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, et al. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene. 2005 Aug 18;24(35):5482–91. doi:10.1038/sj.onc.1208713
   PubMed Web of Science ®Google Scholar
• Hu Y, Qiu Y, Yague E, et al. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 2016 Jun 30;7(6):e2291. doi:10.1038/cddis.2016.194
   PubMedGoogle Scholar
• Lui J, Crepin M, Liu J, et al. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras-ERK pathway. Biochem Biophys Res Commun. 2002;293:8.
   Web of Science ®Google Scholar
• Xian W, Pappas L, Pandya D, et al. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 2009 Mar 15;69(6):2244–51. doi:10.1158/0008-5472.CAN-08-3398
   PubMed Web of Science ®Google Scholar
• Xian W, Schwertfeger KL, Vargo-Gogola T, et al. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol. 2005 Nov 21;171(4):663–73. doi:10.1083/jcb.200505098
   PubMed Web of Science ®Google Scholar
• Rykala J, Przybylowska K, Majsterek I, et al. The −553 T/A polymorphism in the promoter region of the FGF2 gene is associated with increased breast cancer risk in Polish women. Arch Med Sci. 2015 Jun 19;11(3):619–27. doi:10.5114/aoms.2013.35996
   PubMed Web of Science ®Google Scholar
• Rykala J, Przybylowska K, Majsterek I, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res. 2011 Dec;17(4):809–17. doi:10.1007/s12253-011-9387-6
   PubMed Web of Science ®Google Scholar
• Sauter ER, Scott S, Hewett J, et al. Biomarkers associated with breast cancer are associated with obesity. Cancer Detect Prev. 2008;32(2):149–55. doi:10.1016/j.cdp.2008.06.002
   PubMedGoogle Scholar
• Hsiung R, Zhu W, Klein G, et al. High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J. 2002;8(4):7. doi:10.1097/00130404-200207000-00006.
   Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010 Mar 01;70(5):2085–94. doi:10.1158/0008-5472.CAN-09-3746
   PubMed Web of Science ®Google Scholar
• Agarwal D, Pineda S, Michailidou K, et al. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer. 2014 Feb 18;110(4):1088–100. doi:10.1038/bjc.2013.769
   PubMed Web of Science ®Google Scholar
• Slattery ML, John EM, Stern MC, et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013 Aug;140(3):587–601. doi:10.1007/s10549-013-2644-5
   PubMed Web of Science ®Google Scholar
• Maehle B, Tretly S, Skjaerven R, et al. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesterone receptor status [Primary]. Breast Cancer Res Treat. 2001;68:10. doi:10.1023/A:1011977118921.
   Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215–66. doi:10.1002/wdev.176
   PubMed Web of Science ®Google Scholar
• Harbinski F, Craig VJ, Sanghavi S, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2012 Oct;2(10):948–59. doi:10.1158/2159-8290.CD-12-0237
   PubMed Web of Science ®Google Scholar
• Shaw KR, Wrobel CN, Brugge JS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):297–310. doi:10.1007/s10911-004-1402-z
   PubMed Web of Science ®Google Scholar
• Homer-Bouthiette C, Doetschman T, Xiao L, et al. Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis. J Biol Chem. 2014 Dec 26;289(52):36303–14. doi:10.1074/jbc.M114.619569
   PubMed Web of Science ®Google Scholar
• Pan RL, Xiang LX, Wang P, et al. Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of Delta-like1. Hepatology. 2015 May;61(5):1708–20. doi:10.1002/hep.27649
   PubMed Web of Science ®Google Scholar
• Kole D, Grella A, Dolivo D, et al. High molecular weight FGF2 isoforms demonstrate canonical receptor-mediated activity and support human embryonic stem cell self-renewal. Stem Cell Res. 2017 May;21:106–116. doi:10.1016/j.scr.2017.04.006
   PubMed Web of Science ®Google Scholar
• Mydlo JH, Kral JG, Macchia RJ. Preliminary results comparing the recovery of basic fibroblast growth factor (FGF-2) in adipose tissue and benign and malignant renal tissue. J Urol. 1998 Jun;159(6):2159–2163. doi:10.1016/S0022-5347(01)63298-1.
   PubMed Web of Science ®Google Scholar
• Kuhn MC, Willenberg HS, Schott M, et al. Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation. Mol Cell Endocrinol. 2012 Feb 26;349(2):180–8. doi:10.1016/j.mce.2011.10.018
   PubMed Web of Science ®Google Scholar
• Hao RH, Guo Y, Dong SS, et al. Associations of Plasma FGF2 levels and polymorphisms in the FGF2 Gene with obesity phenotypes in Han Chinese Population. Sci Rep. 2016 Feb 16;6:19868. doi:10.1038/srep19868
   PubMed Web of Science ®Google Scholar
• Grazul-Bilska A, Reynolds L, Bilski J, et al. Effects of basic fibroblast growth factor (FGF-2) on proliferation of human skin fibroblasts in type II diabetes mellitus. Exp Clin Endocrinol Diabetes. 2002 2002;110(4):176–181. doi:10.1055/s-2002-32149.
   PubMed Web of Science ®Google Scholar
• Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol. 2013 Sep 06;4:247. doi:10.3389/fphys.2013.00247
   PubMed Web of Science ®Google Scholar
• Matsui R, Brody J, Yu Q. FGF-2 induces surfactant protein gene expression in foetal rat lung epithelial cells through a MAPK-independent pathway. Elsevier. 1999;11(3):221–228.
   Google Scholar
• Gabrielsson B, Johansson J, Jennische E, et al. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes Res. 2002;10(7):608–17. doi:10.1038/oby.2002.83.
   PubMedGoogle Scholar
• Wang YY, Lehuede C, Laurent V, et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett. 2012 Nov 28;324(2):142–51. doi:10.1016/j.canlet.2012.05.019
   PubMed Web of Science ®Google Scholar
• Zhao M, Sachs PC, Wang X, et al. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biol Ther. 2012 Jul;13(9):782–92. doi:10.4161/cbt.20561
   PubMed Web of Science ®Google Scholar